Jean-Pierre Riveline
Prof Jean-Pierre Riveline is an expert in Endocrinology at Hôpital Lariboisière (France). As of October 2026, ScienceLeadR ranks Jean-Pierre Riveline in the top 1% of experts worldwide for Diabetes Mellitus, Glucose Metabolism Disorders and Autoimmune Diseases. Jean-Pierre Riveline has authored 258 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 11 of them ongoing. SLR score: 1,181 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Public Health - Gastroenterology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Jean-Pierre Riveline is Professor of Endocrinology and Diabetology at Lariboisière Hospital and University Paris-Cité in Paris, France. He is the leader of the University Center for Diabetes and its Complications (CUDC).
Jean-Pierre Riveline has been interested for several years in new technologies for patients living with diabetes, especially continuous glucose monitoring and Automated Insulin Delivery (AID). He has conducted several studies evaluating the effectiveness of CGM.
He works in the development of a test bench for the evaluation of pump, CGMs, and AID.
He is also developing an islet transplantation program for people living with a type 1 diabetes in Paris.
He is the coordinator for two national cohorts: SFDT1, a long-term prospective follow-up of patients living with type 1 diabetes to better understand cardiovascular risk in this population and OB2F, a real-life cohort evaluating the efficacy and safety of closed-loop Automated Insulin Delivery.
Organizations
Career arc: 2003 - 2026
Number : 258
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 29
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
11 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diabetes 2024-519494-19-00 — diabetes mellitus, safety, metabolic diseases, nutritional and metabolic diseases, diabetes mellitus, type 1 | Phase 3 | Recruiting | 2025 |
| Omnipod 5 A French Prospective Multicentric Study in Real World (Optimal B) NCT07317102 — diabetes mellitus, registries, insulin, aged, diabetes mellitus, type 1, continuous glucose monitoring | N/A | Recruiting | 2026 |
| The Real World Control IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France NCT07211126 — diabetes mellitus, quality of life, insulin, hypoglycemia, diabetes mellitus, type 1, glycemic control | N/A | Recruiting | 2026 |
| INNODIA Family Friends Early Stage T1D Detection Protocol NCT07118098 — diabetes mellitus, cells, autoantibodies, blood glucose, insulin, blood, glucose intolerance, signs and symptoms, diabetes mellitus, type 1, child | N/A | Recruiting | 2025 |
| French Prospective Multicentric Study in Real World NCT07039942 — diabetes mellitus, registries, insulin, aged, diabetes mellitus, type 1, continuous glucose monitoring | N/A | Active not recruiting | 2025 |
LeadR Networks
Main global connection map